The Effect of Some Parturients' Characteristics on Sensory Block Level After Spinal Anesthesia

Assiut University

Status and phase: Unknown; Phase 4

Conditions: Anesthesia, Obstetrical

Treatments: Drug: Bupivacaine Hydrochloride

Study type: Interventional

Funder types: Other

Identifiers

NCT03164096

obstanesth

Details and patient eligibility

About

Although the exact mechanism remains unknown, the association of pregnancy and decreased local anesthetic requirement is clear. demonstrated that more local anesthetic is required for cesarean section under combined spinal-epidural anesthesia in preterm compared with term patients.

Full description

However, in pregnant patients, venous engorgement is prominent in the supine but not the lateral position, which suggests direct compression of the inferior vena cava by the gravid uterus. Second, an increase in intraabdominal pressure may affect the retroperitoneal area and may cause inward movement of soft tissue in the intervertebral foramina. Recent magnetic resonance imaging studies in pregnant patients, although without intraabdominal pressure measurements, suggested the latter because they showed limited contact of engorged veins along the dural sac which may therefore not be responsible for compression of the dura.

If elevated intraabdominal pressure contributes to high anesthetic spread during pregnancy, one would expect a relationship between intraabdominal pressure and maximum sensory block level.

Enrollment: 100 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult female partner
• aged 18 to 40 years.
• scheduled for elective cesarean section.

Exclusion criteria

• Patients with coagulopathy or under anti-coagulation therapy.
• Gastrointestinal disease,
• motion sickness.
• diabetes mellitus.
• Patients with preeclampsia,

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

intrathecal bupivacaine

Experimental group

Description:

intrathecal bupivacaine hydrochloride 0.5%,12.5mg

Treatment:

Drug: Bupivacaine Hydrochloride